Foresite Capital Management is a fast-growing American company specializing in genomics and drug development investments. Foresite’s mandate is not only restricted to financing experimental treatments. No, their focus extends to encapsulate making investments in emerging diagnostics, medical devices and, on promising healthcare services. Under the able-stewardship of CEO Jim Tananbaum, the sky is no longer the limit for this organization based in San Francisco, CA, anymore. Foresite Capital has now turned its gaze on taking over the entire pharmaceutical industry.
Dr. Molly He Joins Foresite
The ambitious expansion strategy of the company recently saw them hire another highly-experienced top-level administrator. In April this year, Foresite made the announcement that they’d secured the services of Dr. Molly He to the partnership. The new signing is expected to come with a ton of positive developments, especially in the research and development department. Dr. Molly is a Ph.D. holder whose worked in the genome and pharmaceutical arena for the past 15 years. Previous to joining Foresight Capital, the revered research scientist served as one of the lead directors over at Illumina Inc.
Next-Gen Sequencing Expert
Speaking to the press shortly after the announcement, the CEO of Foresite, Jim Tananbaum couldn’t hide his joy and excitement about having Dr. Molly come work with them. After all, Molly has risen to become one of the leading authority voices in the field of next generation DNA and genome sequencing techniques. Jim referred to Dr. Molly as being an invaluable asset to Foresite and its growth prospects, moving forward.
Targeted Cancer Attacks
At her previous gig, Dr. Molly He was mostly in charge of overseeing experiments involving improving our understanding of protein reagents. The new partner has a wealth of experience working with synthetically engineered antibodies and other drugs which target cancerous cells and other autoimmune disorders prevalent in the world today. According to Pehub.com, Dr. Molly is the proud holder of well over 20 patents on the realm of next-generation sequencing. You can visit Peloton Therapeutics for more info.
About Jim Tananbaum
Jim is a highly respected medical researcher who attended the Harvard Medical School in the mid-to-late 80’s. Mr. Tananbaum pursued two different degrees at the same time. He balanced his medical studies with Informational Theory courses from MIT. Upon graduating, Jim didn’t start his medical career right away. Instead, he opted to increase his knowledge and that’s when he enrolled at the Harvard Business School. Jim completed his MBA studies at Harvard in 1991. The CEO has remained at Foresite Capital, based in San Francisco, for the last 7 years.